Stock CHEMCRUX6 CHEMCRUX ENTERPRISES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Chemcrux Enterprises Limited

Equities

CHEMCRUX6

INE298W01016

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:52 2024-06-20 am EDT 		5-day change 1st Jan Change
233.7 INR +1.39% Intraday chart for Chemcrux Enterprises Limited -0.49% -23.98%
May. 06 Chemcrux Enterprises Limited Recommends Final Dividend for Fiscal Year 2023-24 CI
May. 06 Chemcrux Enterprises Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 165.4 419.6 335.4 715.8 2,266 4,399
Enterprise Value (EV) 1 187.4 378.8 260.9 611.6 2,165 4,326
P/E ratio 7 x 4.5 x 3.15 x 8.01 x 15.2 x 30.6 x
Yield 0.75% 0.59% 5.89% 1.38% 1.31% 0.67%
Capitalization / Revenue 0.53 x 0.76 x 0.58 x 1.34 x 2.38 x 4.62 x
EV / Revenue 0.6 x 0.69 x 0.45 x 1.15 x 2.27 x 4.55 x
EV / EBITDA 3.89 x 2.64 x 1.75 x 4.71 x 10.3 x 20.2 x
EV / FCF -22.5 x 9 x 8.06 x 54.6 x 1,594 x 38.5 x
FCF Yield -4.44% 11.1% 12.4% 1.83% 0.06% 2.59%
Price to Book 1.13 x 1.76 x 1.03 x 1.75 x 4.14 x 6.62 x
Nbr of stocks (in thousands) 14,809 14,809 14,809 14,809 14,809 14,809
Reference price 2 11.17 28.33 22.65 48.33 153.0 297.0
Announcement Date 8/24/18 8/21/19 7/16/20 7/29/21 8/31/22 8/18/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 314.6 552.7 574.5 533.3 952.7 951.5
EBITDA 1 48.21 143.5 148.9 130 209.7 214.4
EBIT 1 41.51 130.9 137.2 118 195.2 195.3
Operating Margin 13.19% 23.69% 23.88% 22.12% 20.49% 20.53%
Earnings before Tax (EBT) 1 40.43 123.7 141 120 200.1 196.5
Net income 1 23.63 93.16 106.4 89.34 149.2 143.6
Net margin 7.51% 16.85% 18.53% 16.75% 15.66% 15.09%
EPS 2 1.596 6.291 7.187 6.033 10.07 9.696
Free Cash Flow 1 -8.319 42.1 32.39 11.2 1.358 112.2
FCF margin -2.64% 7.62% 5.64% 2.1% 0.14% 11.8%
FCF Conversion (EBITDA) - 29.34% 21.75% 8.62% 0.65% 52.35%
FCF Conversion (Net income) - 45.19% 30.43% 12.54% 0.91% 78.17%
Dividend per Share 2 0.0833 0.1667 1.333 0.6667 2.000 2.000
Announcement Date 8/24/18 8/21/19 7/16/20 7/29/21 8/31/22 8/18/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 22.1 - - - - -
Net Cash position 1 - 40.8 74.5 104 101 72.8
Leverage (Debt/EBITDA) 0.4577 x - - - - -
Free Cash Flow 1 -8.32 42.1 32.4 11.2 1.36 112
ROE (net income / shareholders' equity) 17.4% 48.3% 37.8% 24.4% 31.2% 23.7%
ROA (Net income/ Total Assets) 11% 25% 20.6% 15.8% 18.6% 13.4%
Assets 1 215.8 372.3 516.2 564.8 803.8 1,075
Book Value Per Share 2 9.920 16.10 21.90 27.60 37.00 44.80
Cash Flow per Share 2 1.030 2.140 1.950 1.830 8.010 0.8300
Capex 1 31.4 25.8 53.8 61.6 58.7 -
Capex / Sales 9.98% 4.66% 9.36% 11.55% 6.16% -
Announcement Date 8/24/18 8/21/19 7/16/20 7/29/21 8/31/22 8/18/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
CHEMCRUX ENTERPRISES LIMITED Stock Chemcrux Enterprises Limited
-23.98% 40.92M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+53.80% 803B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.38% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.43% 324B
ABBVIE INC. Stock AbbVie Inc.
+11.30% 303B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.96% 243B
ROCHE HOLDING AG Stock Roche Holding AG
+2.25% 228B
NOVARTIS AG Stock Novartis AG
+11.15% 217B
AMGEN INC. Stock Amgen Inc.
+6.57% 164B
PFIZER, INC. Stock Pfizer, Inc.
-3.44% 155B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CHEMCRUX6 Stock
  4. Financials Chemcrux Enterprises Limited